Nitto Avecia
Mark Boyle, MBA, CSSBB has a diverse work experience spanning over several years. Mark is currently serving as the Director of Operations and Program Management at Nitto Denko Avecia Inc. since January 2015. Prior to that, they worked as the Operations Program Manager (Operational Excellence) at Avecia Biotechnology, a Nitto Denko Company, from December 2010 to January 2015. From December 2007 to January 2010, they held the position of Director of Vaccines Manufacturing & Supply at PharmAthene. Before that, they worked as the Director of Strategy Management at Avecia Biotechnolgy from January 2006 to December 2007. Mark started their career at Avecia Biotechnology in June 2002 as a Sr. Project Manager, where they stayed until January 2006. Overall, Mark Boyle has a substantial experience in operations, program management and strategy in the biotechnology industry.
Mark Boyle, MBA, CSSBB, has a diverse education history. Mark began their academic journey by obtaining a Manufacturing Certificate in Supply Chain Management from the University of Warwick - Warwick Business School in 2005. Following this, they pursued a degree in Leadership and completed an MBA program at Johnson & Wales University from 2005 to 2006.
Prior to their MBA, Boyle attended Roger Williams University and earned a Bachelor of Science degree in Mechanical Engineering/Mechanical Technology/Technician from 1988 to 1991.
In terms of additional certifications, Boyle obtained an ASQ Certified Six Sigma Black Belt from ASQ in October 2013. Furthermore, they acquired a certification in Unconscious Bias from LinkedIn in October 2020.
Nitto Avecia
1 followers
Oligonucleotides are giving rise to a new generation of therapeutics—and Nitto Avecia is helping lead the way. With more than 25 years’ experience in oligonucleotide development and production, we are the partner of choice for pharmaceutical innovators creating new drugs with the power to transform treatment for a wide range of diseases. In partnership with Nitto Avecia Pharma Services, Nitto Avecia is the first CMO that offers a comprehensive, end-to-end oligonucleotide solution. This offers the advantage of a single, expert partner handling the entire process—from drug substance through drug product manufacturing—with flexible solutions and consistent reliability and quality.